Convalescent plasma to treat COVID-19 | Blood | American Society of Hematology
In this issue of Blood, Hegerova et al report on a study of 20 hospitalized patients with severe or critical coronavirus disease 2019 (COVID-19) who were transf
In this issue of Blood, Hegerova et al report on a study of 20 hospitalized patients with severe or critical coronavirus disease 2019 (COVID-19) who were transf
We are sorry, but we are experiencing unusual traffic at this time. Please help us confirm that you are not a robot and we will…
We are sorry, but we are experiencing unusual traffic at this time. Please help us confirm that you are not a robot and we will…
Pier Luigi Zinzani, Gilles A. Salles, Alison J Moskowitz, Armando Santoro, Amitkumar Mehta, Paul M. Barr, Neha Mehta-Shah, Graham P. Collins, Stephen M. An
We are sorry, but we are experiencing unusual traffic at this time. Please help us confirm that you are not a robot and we will…
Casan and Seymour provide a state-of-the-art review of proteolysis-targeting chimeras (PROTACs), the leading class of targeted protein degradation agents.
Blood | 143 | 13 | March 2024
Podcasts | The Hematologist | American Society of Hematology Podcasts The Hematologist offers podcasts that enhance the reading experience by presenting key results and additional insights…
Blood Neoplasia | 1 | 1 | March 2024
We are sorry, but we are experiencing unusual traffic at this time. Please help us confirm that you are not a robot and we will…
Key Points. We show that patients gradually recover CD38 antibody sensitivity while on other treatments.We conclude that re-treatment efficacy may improve by wa